九芝堂(000989.SZ):擬向併購基金追加投資1億元 進一步提升Stemedica與北京美科協同性效應
格隆匯12月10日丨九芝堂(000989.SZ)公佈,公司於2021年12月10日召開第八屆董事會第七次會議,審議通過了《關於向併購基金追加投資認購基金份額暨關聯交易的議案》。公司根據戰略規劃與投資計劃,決定以自有資金向併購基金追加投資人民幣1億元,以認購併購基金份額。公司此次追加投資後,併購基金總規模為人民幣9億元,其中,普通合夥人北京納蘭德認繳總額為人民幣900萬元;有限合夥人九芝堂股份有限公司認繳總額為人民幣7億元;未來將引入的有限合夥人認繳總額為人民幣1.91億元。該議案獲得董事會審議批准後,公司及北京納蘭德將就追加投資事項重新簽署《珠海橫琴九芝堂雍和啟航股權投資基金(有限合夥)合夥協議》。
公司通過此次投資將滿足目前併購基金投資項目的業務發展對資金的需求,進一步提升Stemedica公司與北京美科協同性效應,加快公司幹細胞項目的研發進程,推動公司幹細胞業務體系發展戰略實施。此次投資使用公司自有資金,不影響公司正常的生產經營活動。
另外,由於併購基金投資的Stemedica公司目前尚未產生盈利,處於虧損狀態,此次投資後,隨着公司間接持有 Stemedica公司股權比例進一步增加,Stemedica公司的虧損金額對公司淨利潤的影響將增大。同時,隨着投資分步實施,併購基金對Stemedica 公司控制力逐步提升,根據會計準則要求,併購基金可能將Stemedica 公司納入其合併報表。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.